Prothena Co. plc (NASDAQ:PRTA - Get Free Report)'s stock price shot up 5.7% during mid-day trading on Tuesday . The company traded as high as $18.59 and last traded at $18.59. 105,632 shares changed hands during mid-day trading, a decline of 82% from the average session volume of 587,920 shares. The stock had previously closed at $17.59.
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on PRTA. Bank of America dropped their price target on shares of Prothena from $33.00 to $31.00 and set a "neutral" rating for the company in a research note on Tuesday, October 1st. Cantor Fitzgerald reiterated an "overweight" rating on shares of Prothena in a research note on Monday, September 30th. Royal Bank of Canada lowered their target price on shares of Prothena from $28.00 to $24.00 and set a "sector perform" rating for the company in a research note on Friday, August 9th. HC Wainwright reiterated a "buy" rating and set a $84.00 target price on shares of Prothena in a research note on Tuesday, October 1st. Finally, StockNews.com upgraded shares of Prothena from a "sell" rating to a "hold" rating in a research note on Monday, August 12th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $61.86.
View Our Latest Stock Report on Prothena
Prothena Price Performance
The firm has a market cap of $983.10 million, a price-to-earnings ratio of -18.28 and a beta of 0.17. The firm's fifty day moving average is $19.34 and its two-hundred day moving average is $20.69.
Prothena (NASDAQ:PRTA - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $1.22 earnings per share for the quarter, topping the consensus estimate of ($1.01) by $2.23. The business had revenue of $132.01 million during the quarter, compared to the consensus estimate of $10.73 million. Prothena had a negative net margin of 23.44% and a negative return on equity of 9.00%. The company's quarterly revenue was up 3184.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.03) earnings per share. On average, equities analysts forecast that Prothena Co. plc will post -2.34 earnings per share for the current fiscal year.
Institutional Trading of Prothena
Hedge funds have recently bought and sold shares of the company. Signaturefd LLC lifted its stake in Prothena by 182.1% during the second quarter. Signaturefd LLC now owns 1,337 shares of the biotechnology company's stock valued at $28,000 after buying an additional 863 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in Prothena by 265.9% during the fourth quarter. PNC Financial Services Group Inc. now owns 1,544 shares of the biotechnology company's stock valued at $56,000 after buying an additional 1,122 shares in the last quarter. Headlands Technologies LLC acquired a new position in shares of Prothena in the 1st quarter valued at about $96,000. Focused Wealth Management Inc increased its holdings in shares of Prothena by 7,751.9% in the 1st quarter. Focused Wealth Management Inc now owns 10,129 shares of the biotechnology company's stock valued at $251,000 after purchasing an additional 10,000 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Prothena by 13.1% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,236 shares of the biotechnology company's stock valued at $211,000 after purchasing an additional 1,186 shares during the period. 97.08% of the stock is owned by hedge funds and other institutional investors.
About Prothena
(
Get Free Report)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Read More
Before you consider Prothena, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prothena wasn't on the list.
While Prothena currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
